Moustakli Efthalia, Grigoriadis Themos, Stavros Sofoklis, Potiris Anastasios, Zikopoulos Athanasios, Gerede Angeliki, Tsimpoukis Ioannis, Papageorgiou Charikleia, Louis Konstantinos, Domali Ekaterini
Laboratory of Medical Genetics, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45110 Ioannina, Greece.
First Department of Obstetrics and Gynecology, Alexandra Hospital, Medical School, National and Kapodistrian University of Athens, 11528 Athens, Greece.
Diagnostics (Basel). 2025 Aug 19;15(16):2075. doi: 10.3390/diagnostics15162075.
Fertility potential ever more diminishes due to the complex, multifactorial, and still not entirely clarified process of reproductive aging in women and men. Gamete quality and reproductive lifespan are compromised by biologic factors like mitochondrial dysfunction, increased oxidative stress (OS), and incremental telomere shortening. Clinically confirmed biomarkers, including follicle-stimulating hormone (FSH) and anti-Müllerian hormone (AMH), are used to estimate ovarian reserve and reproductive status, but these markers have limited predictive validity and an incomplete representation of the complexity of reproductive age. Recent advances in artificial intelligence (AI) have the capacity to address the integration and interpretation of disparate and complex sets of data, like imaging, molecular, and clinical, for consideration. AI methodologies that improve the accuracy of reproductive outcome predictions and permit the construction of personalized treatment programs are machine learning (ML) and deep learning. To promote fertility evaluations, here, as part of its critical discussion, the roles of mitochondria, OS, and telomere biology as latter-day biomarkers of reproductive aging are presented. We also address the current status of AI applications in reproductive medicine, promises for the future, and applications involving embryo selection, multi-omics set integration, and estimation of reproductive age. Finally, to ensure that AI technology is used ethically and responsibly for reproductive care, model explainability, heterogeneity of data, and other ethical issues remain as residual concerns.
由于男性和女性生殖衰老过程复杂、多因素且仍未完全阐明,生育潜力日益下降。配子质量和生殖寿命受到线粒体功能障碍、氧化应激(OS)增加和端粒逐渐缩短等生物学因素的影响。临床确诊的生物标志物,包括促卵泡激素(FSH)和抗苗勒管激素(AMH),用于评估卵巢储备和生殖状态,但这些标志物的预测有效性有限,且不能完全体现生殖年龄的复杂性。人工智能(AI)的最新进展有能力处理不同类型的复杂数据,如图像、分子和临床数据,以供综合分析。提高生殖结果预测准确性并允许构建个性化治疗方案的AI方法是机器学习(ML)和深度学习。为促进生育评估,本文作为批判性讨论的一部分,阐述了线粒体、OS和端粒生物学作为生殖衰老现代生物标志物的作用。我们还探讨了AI在生殖医学中的应用现状、未来前景,以及在胚胎选择、多组学数据整合和生殖年龄评估方面的应用。最后,为确保AI技术在生殖保健中得到道德和负责任的使用,模型可解释性、数据异质性和其他伦理问题仍是需要关注的遗留问题。